In the last trading session, 1.3 million shares of the Vistagen Therapeutics Inc (NASDAQ:VTGN) were traded, and its beta was 0.36. Most recently the company’s share price was $2.46, and it changed around $0.25 or 11.31% from the last close, which brings the market valuation of the company to $71.73M. VTGN currently trades at a discount to its 52-week high of $4.21, offering almost -71.14% off that amount. The share price’s 52-week low was $1.90, which indicates that the current value has risen by an impressive 22.76% since then. We note from Vistagen Therapeutics Inc’s average daily trading volume that its 10-day average is 0.34 million shares, with the 3-month average coming to 159.06K.
Vistagen Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended VTGN as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight.
Vistagen Therapeutics Inc (NASDAQ:VTGN) trade information
Instantly VTGN has showed a green trend with a performance of 11.31% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 2.62 on recent trading dayincreased the stock’s daily price by 6.11%. The company’s shares are currently down -25.68% year-to-date, but still up 23.00% over the last five days. On the other hand, Vistagen Therapeutics Inc (NASDAQ:VTGN) is 3.80% up in the 30-day period. We can see from the shorts that 0.48 million shares have been sold at a short interest cover period of 2.92 day(s).
The consensus price target as assigned by Wall Street analysts is $6, which translates to bulls needing to increase their stock price by 59.0% from its current value. Analyst projections state that VTGN is forecast to be at a low of $6 and a high of $6.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 35.63%. Vistagen Therapeutics Inc earnings are expected to increase by 8.08% in 2025, but the outlook is positive 29.31% per year for the next five years.
VTGN Dividends
Vistagen Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Jun-02.
Vistagen Therapeutics Inc (NASDAQ:VTGN)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.26% of Vistagen Therapeutics Inc shares, and 52.90% of them are in the hands of institutional investors. The stock currently has a share float of 53.04%. Vistagen Therapeutics Inc stock is held by 56.0 institutions, with TCG CROSSOVER MANAGEMENT, LLC being the largest institutional investor. By 2024-06-30, it held 13.8292% of the shares, which is about 2.68 million shares worth $9.31 million.
BVF INC/IL, with 6.5352% or 2.0 million shares worth $6.96 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
